Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015674 (chronic fatigue syndrome)
 2,978 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chronic fatigue syndrome (CFS) has been widely studied by neuroimaging techniques in recent years with conflicting results. In particular, using single-photon emission computed tomography (SPECT) and perfusion tracers, hypoperfusion has been found in several brain regions, although the findings vary across research centers. The objective of this study was to investigate brain metabolism of patients affected by CFS, using [18F]fluorine-deoxyglucose (18FDG) positron emission tomography (PET). We performed 18FDG PET in 18 patients who fulfilled the criteria of the working case definition of CFS. Twelve of the 18 patients were females; the mean age was 34 +/- 15 years (range, 15-68) and the median time from CFS diagnosis was 16 months (range, 9-138). Psychiatric diseases and anxiety/neurosis were excluded in all CFS patients. CFS patients were compared with a group of 6 patients affected by depression (according to DSM IV-R) and 6 age-matched healthy controls. The CFS patients were not taking any medication at the time of PET, and depressed patients were drug-free for at least 1 week before the PET examination. The PET images examined 22 cortical and subcortical areas. CFS patients showed a significant hypometabolism in right mediofrontal cortex (P = 0.010) and brainstem (P = 0.013) in comparison with the healthy controls. Moreover, comparing patients affected by CFS and depression, the latter group showed a significant and severe hypometabolism of the medial and upper frontal regions bilaterally (P = 0.037-0.001), whereas the metabolism of brain stem was normal. Brain 18FDG PET showed specific metabolism abnormalities in patients with CFS in comparison with both healthy controls and depressed patients. The most relevant result of our study is the brain stem hypometabolism which, as reported in a perfusion SPECT study, seems to be a marker for the in vivo diagnosis of CFS.
 ...
PMID:Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. 979 Apr 83

Carbon-Fluorine Spectroscopy (CFS(TM)), also known as Fluoro-Raman Spectroscopy (FRS(TM)), is a relatively new patented platform technology using a family of various methods and cost-effective devices called PLIRFATM (Pulsed Laser Isochronic Raman and Fluorescence Apparatus) developed by Fluorotronics, Inc. The key feature of this progressive and non-destructive technology is based on the discovery of a characteristic optical signature of carbon-fluorine bond(s) in the fingerprint spectral area of 500-800 cm(-1) allowing rapid, ultra-specific and sensitive detection, characterization, imaging, and measurement of any fluoroorganics. Interestingly, the C-F bond is unique in its character and so it can be used as a molecular label. Furthermore, the C-F label is efficient, soluble, cheaper, smaller, more stable and less toxic than fluorescent dyes, nanoparticles or quantum dot materials. Thereby, C-F bonds are often incorporated into pharmaceutical, agrochemical and biological molecules in addition to polymers and nano-materials to achieve special properties (e.g. molecular stability, molecular tracing). In this paper, we present some of our data obtained from FRS(TM) applied to pharmaceuticals and biologics, and provide perspectives of FRS applications for the pharmaceutical and biomedical fields.
 ...
PMID:Development of carbon-fluorine spectroscopy for pharmaceutical and biomedical applications. 2141 85